CMX-2043 / Ischemix - LARVOL DELTA

CMX-2043 Treatment Limits Neural Injury Pathophysiology and Promotes Neurological and Cognitive Recovery in a Pediatric Porcine Traumatic Brain Injury Model. (PubMed, J Neurotrauma) - "These cellular and tissue-level changes corresponded with reduced neurological deficits and rapid cognitive recovery as indicated by improved mRS and SRT results, respectively. Collectively, these results observed in a translational large animal porcine model suggest that CMX-2043 holds significant clinical value to potentially mitigate TBI pathophysiology and promote functional recovery."

Journal • Preclinical • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Inflammation • Pediatrics • Vascular Neurology

Catalase Activity in the Brain Is Associated with Recovery from Brain Injury in a Piglet Model of Traumatic Brain Injury. (PubMed, Brain Sci) - "This study examines the neuroprotective effects of the novel antioxidant alpha lipoic acid-based therapeutic, CMX-2043, on antioxidant enzymes in a preclinical TBI model via various drug administration routes... This study highlights the impact of administration route on tissue-specific antioxidant responses, with IV administration enhancing liver catalase and brain SOD activity, while SQ administration primarily elevated brain catalase activity. In addition, this study shows an association between increased brain catalase activity and decreased TBI brain lesioning, midline shift, and combined swelling and atrophy, thus emphasizing the role of antioxidant defenses in neuroprotection post-injury."

Journal • CNS Disorders • Pediatrics • Vascular Neurology • CAT

Interaction of Asparagusic Acid, Asparaptines and Related Dithiolane Derivatives With Angiotensin-Converting Enzyme-2 (ACE-2): A Molecular Docking Study. (PubMed, J Biochem Mol Toxicol) - "Both the l-Glu-l-Ala dipeptide motif and the α-lipoic acid moiety of CMX-2043 are implicated in the protein interaction. Our observations pave the way to the design of novel ligands of ACE2 equipped with a dithiolane motif."

Journal

In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking. (PubMed, Int J Mol Sci) - "Adding the energy contributions of affinity for non-covalent and covalent docking, 16 promising drugs were obtained. Our findings suggest that the FDA-approved drugs Vaborbactam, Cimetidine, Ixazomib, Scopolamine, and Bicalutamide, as well as the other investigational peptide-like drugs (DB04234, DB03456, DB07224, DB7252, and CMX-2043) are potential covalent inhibitors of SARS-CoV-2 M."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

RANDOMIZED, BLINDED, PLACEBO-CONTROLLED PRECLINICAL TRIAL IN A LARGE ANIMAL TBI MODEL (SCCM 2022) - "Following five days of treatment with CMX-2043, treatment animals had significantly higher FA values compared to placebo, demonstrating preservation in structural integrity of the white matter following injury. There was no difference in cerebral edema at five days post-TBI as measured by DTI MRI MD."

Preclinical • Anesthesia • CNS Disorders • Vascular Neurology

EFFECTS ON MITOCHONDRIAL DYNAMICS FOLLOWING THERAPEUTIC INTERVENTION IN LARGE ANIMAL TBI MODEL (SCCM 2022) - "Subjects treated with an ALA analogue, CMX-2043, had significantly lower expression of DRP1, fission, 5 days post-TBI. There was no significant difference in OPA1 expression, fusion, at the same time-point, signaling that fusion activity did not appear to be affected by CMX-2043. Further investigation is required to better characterize the influences and tendencies of mitochondrial dynamics following injury."

CNS Disorders • Vascular Neurology

Reduction in Reaction Oxygen Species With Novel Intervention Following TBI in a Large Animal Model (SCCM 2022) - "Treatment with CMX-2043 demonstrated a statistically significant reduction in mtROS, lipid peroxidation and improved mitochondrial function at 24-hours post-TBI in a large animal model."

Preclinical • Anesthesia • CNS Disorders • Vascular Neurology

Alpha-lipoic acid analogues in the regulation of redox balance in epilepsy: A molecular docking and simulation study. (PubMed, J Mol Graph Model) - "Our findings provide new insights into additional mechanisms of action, which may in part, account for the antioxidant properties associated with alpha-lipoic acid and related analogues. The results support further in vitro and in vivo evaluation of these compounds to better understand their potential as add-on therapy for ASM treatment in epilepsy."

Journal • CNS Disorders • Epilepsy • SOD2

SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention. (PubMed, J Cardiovasc Pharmacol) - "These data suggest that CMX-2043 may reduce PCI periprocedural myonecrosis and support further clinical evaluation of this novel agent for its potential cytoprotective effects."

Clinical • Journal

Ischemix: Corporate Presentation (Ischemix) - "Cardiac Enzyme Biomarker Concentration Following PCI Procedure"

P2a data • Reperfusion Injury